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Pharmaceuticals and Stem Cells in Autism Spectrum
time show an impaired development of skills associated with interaction, language and coordination.
The prevalence of ASDs is 1 -1.5% in the US. 10, 11 Males are more frequently affected than girls, with a one in 42 boys being diagnosed with an ASD compared to one in 189 girls. Despite the myriad studies conducted on ASDs thus far, the exact etiology and pathophysiology of these disorders remain poorly understood. [12] [13] [14] For instance, although increasing paternal and maternal ages at birth appear to increase the risk of a child developing autism, 15 the underlying molecular processes linking this association to disease pathogenesis remain elusive. In addition, the clear heterogeneity of symptoms between affected individuals very likely reflects the heterogeneity of pathophysiological mechanisms in ASDs. This heterogeneity provides a significant hurdle to the development of broadly applicable diagnostic tools and therapies.
However, recent studies have identified broad abnormalities such as synaptic connectivity problems, excitatory/inhibitory imbalances and white matter disorganization that may account for the impaired development of social and communication skills in children with autism. [16] [17] [18] Moreover, there is growing evidence that various genetic, epigenetic and environmental factors could account for a wide range of neurodevelopmental abnormalities seen in ASDs. 1, [19] [20] [21] In this review, we will outline the main genetic, epigenetic and environmental factors implicated in the etiology of ASDs, followed by an overview of various biomarkers that may prove useful in the diagnosis of ASDs. We will end by discussing the M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT potential of certain drugs, stem cells and nanoparticles as therapeutic options in
ASDs (Figure 1 ).
Genetic/Epigenetic Factors in ASDs
Advances in genetic tools have helped to clarify potential causative factors in autism by enabling the identification of genes associated with ASDs. [22] [23] [24] [25] This genetic approach to elucidating the pathophysiology of ASDs has been adopted by various groups, who utilize a diverse array of investigations, including: copy number variation (CNV) [26] [27] [28] [29] [30] [31] [32] ; single nucleotide polymorphisms [33] [34] [35] [36] ; tandem repeat polymorphisms (TRPs) 37 ; and twin births. 38, 39 These investigations have revealed ASD-associated mutations in a wide variety of genes that ultimately converge on several common biological pathways. For instance, many AD-associated genes appear to be linked directly or indirectly to synaptic plasticity and efficient neurotransmission. In a review of genome-wide association studies conducted so far, Glessner et al. highlighted that the risk for autism was significantly influenced by variation in a number of gene families encoding components in excitatory synapses, such as the neurexin (NRXN),
CACNA, GRM, CNTN gene families. 40 Specifically, mutations in the neurexin (NRXN), 41, 42 as well as in the related neuroligin (NLGN) and ProSAP/Shank gene families, [43] [44] [45] [46] [47] [48] have been shown to increase the risk for ASDs by altering synaptic structure and function. NLGNs are postsynaptic adhesion molecules that bind presynaptic NRXNs with high affinity. By connecting pre-and post-synaptic neurons, they facilitate trans-synaptic signaling and shape neural network properties. At the same time, members of the ProSAP/Shank family such ProSAP2/Shank3 appear to be involved not only in synaptic transmission through AMPA and NMDA receptors, but also in regulation of the density of presynaptic and postsynaptic proteins via neurexin-neuroligin transsynaptic signaling. ASD-associated mutations in any of these components (NRXNs, NLGNs, or ProSAPs/Shanks) could thus interfere with efficient trans-synaptic signaling and with maturation of excitatory synapses within the CNS. 51 Epigenetic regulation of RORA expression via differential DNA methylation has been observed in lymphoblastoid cell lines from discordantly diagnosed monozygotic twins and their nonautistic siblings. In the same study, the cerebellum and frontal cortex of autistic and age-and sex-matched control subjects revealed decreased expression of RORA in the autistic brain. 52 The observation of similar methylation profiles in the brain and peripheral blood could suggest that epigenetic reprogramming is an early developmental event that occurs prior to germ layer specification. In this way, low levels of RORA during neurodevelopment due to DNA methylation could at least partially account for the defects in connectivity that thought to underlie the disease.
Interestingly, the differential expression of RORA in male and female brains could explain the strong 4:1 male bias in ASDs
53
; estrogen is known to increase RORA levels in the brain while testosterone decreases it. Since aromatase, which is activated downstream to RORA, is itself responsible for aromatizing testosterone to estrogen, this sets up a positive feedback loop of decreased RORA expressionwhich may predispose children with high testosterone and low estrogen levels to ASDs. This relationship is depicted in Figures 2 and 3 .
There is also evidence that methylation of the oxytocin receptor (OXTR) gene is associated with autism, high callous-unemotional (CU) traits, and differential activation of brain regions involved in social perception. 55 In one study, DNA methylation analysis of a CpG island known to regulate OXTR expression found that several CpG dinucleotides show increased DNA methylation in the peripheral blood cells and temporal cortex in independent datasets of autistic individuals, as compared to control samples. In agreement with these findings, the same study found decreased OXTR mRNA levels in the temporal cortex tissue of age-and sex-M A N U S C R I P T
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matched autistic individuals compared to controls. 56 At present, our understanding of the chronology, regulation and reversibility of epigenetic programming during fetal development is limited. Future studies are necessary to determine whether loci such as the RORA and OXTR loci are epigenetically labile and susceptible to certain exposures in utero that alter the methylation status of these genes. A more thorough understanding of epigenetic changes during the first few weeks of pregnancy would help clarify how genes and the environment interact in the pathophysiology of ASDs.
Environmental Risk Factors in ASDs
It has been established that genetic, epigenetic and environmental causes are closely interlinked in non-syndromic ASDs. [57] [58] [59] [60] [61] [62] [63] Environmental challenges in particular are known to pose maximum risk during early development. 64 As would be expected, many of these environmental challenges are driven by maternal factors.
Examples include: intake of prenatal and perinatal analgesics 65 ; teratogenic/toxic agents such as thalidomide, valproic acid, ethanol and misoprostol [66] [67] [68] ; frequent prenatal ultrasound recordings inducing birth defects in early pregnancy 67 ; parental occupational hazards such as varnish, xylene and asphalt compounds 69 ; pre-term accumulation of trace metals such as lead, nickel, and arsenic 66, [70] [71] [72] [73] [74] ; potential chemical hazards like organophosphorus pesticides, polychlorinated biphenyls (PCBs) and polyaromatic hydrocarbons (PAHs) 59, 75 ; and highly mutagenic synthetic perfumes and cosmetics. 10 However, it is important to note that there are inherent difficulties in forming definitive links between environment influences and ASDs. For instance, although several lines of study have associated numerous trace metals with an increased risk for autism, a recent study cast doubt on this association by suggesting that only mercury is related to autism. 76 Hence, the matter of labeling heavy metals as a risk factor for ASDs is contentious and remains unresolved.
Immune Dysregulation, Oxidative Stress and Neuroinflammation
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
It has been established that problems with immune function are likely to contribute to the development of ASDs. [77] [78] [79] [80] In fact, immune dysfunctions, oxidative stress, mitochondrial abnormalities and neuroinflammatory processes appear to be mutually reinforcing in patients with ASDs. [81] [82] [83] [84] Results from peripheral biomarker studies emphasize the key roles of both innate and adaptive immune system deregulation in ASDs. 85, 86 Deregulated immune system genes in autistic subjects seem to be important causes of behavioral problems, 85, 87 as well as gastrointestinal complications. 88, 89 Loss of blood brain barrier (BBB) integrity is one of the key pathological steps in the progression of immune dysfunction associated with ASDs. 90, 91 Notably, mast cell activation may lead to gut-blood-brain barrier disruption, as well as brain inflammation.
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Using a mouse model of autism, drastic changes in various immune molecules have been observed 93 ; whilst clinical data suggest that pro-inflammatory cytokine levels can often be correlated with autistic behaviors. 94, 95 Inflammatory cytokine alterations in subjects prone to environmental risks have been evident in several studies, 79, 93, 96 and it is plausible that increased neuroinflammation provoked by elevated cytokines could contribute to observed behavioural dysfunction in autistic individuals.
97-100
Th1-like (IFN-gamma, IL-2) cytokines have been found to be decreased and Th2-like (IL-4, IL-6, and IL-10) cytokines have been found to be increased in autistic children as compared to control groups. 101 An elegant transcirtomic analysisby Gupta et al, found that a gene expression module corresponding to M2-activation states in microglia was elevated in autism cases compared to controls. In addition, this M2-activation state is negatively correlated with a neuronal module corresponding to synaptic transmission genes that appears to be differentially expressed in autism.
The enrichment of genes corresponding to an M2-activation state and simultaneous attenuation of genes implicated in synaptic transmission implicating dysregulated microglial responses in concert with altered neuronal activity-dependent genes in the pathophysiology of autism during early development. 102 Furthermore, maternal IgG antibodies such as those produced in autoimmune disease (e.g. systemic lupus erythematosus) can cross the placenta to the fetus.
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While these antibodies are less likely to cross the adult BBB, the developing BBB in the fetus is more permeable and hence more vulnerable to antibody-mediated damage, as shown in Figure 4 . 96, 103 In fact, Braunschweig et al. found a significant correlation between maternal IgG reactivity to fetal brain proteins and a childhood diagnosis of autism. 104 Altogether, the evidence suggests that environmentally driven peripheral immune dysfunctions and associated neuropathological consequences form a series of interlinked events, which can manifest in autistic features.
As such, although there are a wide variety of genetic, epigenetic and environmental factors that have been implicated in ASDs, these factors are likely to eventually contribute to a specific underlying pathogenic mechanism -such as immune dysfunction -that may be targeted for diagnosis or therapy.
Diagnostic Biomarkers for ASDs
Within ASDs, a complexity of genetic polymorphisms, observed symptoms, and miRNAs, which are small endogenous molecules that bind mRNA and silence genes through the RNA-induced silencing complex, may also be useful diagnostic biomarkers for autism. Circulating miRNAs in the serum and plasma are known to be stable and are increasingly recognized as potential noninvasive biomarkers for neurological and neurodevelopmental disorder. One study found that thirteen miRNAs were differentially expressed in autistic and non-autistic children, as shown in Figure 5 . 111 Using receiver operating characteristic curve analysis to evaluate the trade-off between sensitivity and specificity in diagnostic tests, 112 the study authors found that five of these miRNAs (miR-181b-5p, miR-320a, miR-572, miR-130a-3p
and miR-19b-3p) were highly sensitive and specific for autism.
In keeping with the theme of minimally invasive, peripheral biomarkers for the central . In fact, an extended-release formulation of guanfacine (GXR) has already entered phase III trials in children with ADHD. Similarly, small, controlled studies have indicated a possible improvement in symptoms of hyperactivity in autistic patients given of the psychostimulant methylphenidate. 123 Methylphenidate is a noradrenaline-dopamine reuptake inhibitor that increases catecholamine levels in the brain, and is being extensively studied as treatment in ASDs, either in its own right or in conjunction with other drugs. In fact, an ongoing trial is investigating the concomitant use of methylphenidate and guanfacine in autistic patients.
It is worth noting that the mechanism of action of many promising drugs, as well as their effected changes in neurotransmitter levels of such, are diverse and in some instances contradictory. For instance, guanfacine is thought to decrease overall M A N U S C R I P T
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noradrenergic tone while methylphenidate increases it. This observation reflects the fact that our understanding of the underlying deficits in ASDs, and of how exactly these drugs achieve their therapeutic effect, it is still unclear. What is clear, however, is that because these drugs alter crucial signaling pathways within the brain, adverse The better side-effect profile and promising preliminary data from trials on metabotropic glutamate receptor (mGluR) antagonists suggests that they may be promising pharmacological agents in the treatment of ASDs. In mouse studies, a mGluR antagonist, 2-methyl-6-(phenylethynyl)-pyridine (MPEP), has been shown to enhance social behavior networks in an autistic Balb/c mouse model. 127 At the same time, synaptic defects and LTD problems were ameliorated by a group II mGluR antagonist in a mouse model of Fragile X syndrome, which is trelated to the ASDs.
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In phase II trials, metabotropic glutamate receptor (mGluR) antagonists seem to improve socio-behavioral symptoms in ASDs and Fragile X syndrome. 129-131 These agents thus signify substantial progress towards novel clinically applicable therapeutics.
Many convincing reports emphasize that antipsychotics such as haloperidol and risperidone can reduce the majority of ASD symptoms at relatively low doses. For instance, the first placebo-controlled trial of risperidone in autism, which involved 31 adults with ASDs, found that risperidone at a mean dose of 2.9 mg/d was significantly more efficacious than placebo. Fifty-seven per cent subjects on risperidone showed an improvement in the Clinical Global Impression-Improvement M A N U S C R I P T
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scale, compared to none of the subjects on placebo. Specifically, risperidone appeared to reduce repetitive behavior as well as aggression toward the self, others, and property. However, although antipsychotics offer some promise, extrapyramidal side effects such as tardive dyskinesia with typical antipsyhcotics, as well as metabolic side effects such weight gain and dyslipidaemia with atypical antipsychotics, remain a major concern.
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Other drugs being newly explored as potential therapeutic options include thiazolidinediones such as pioglitazone that are used in type 2 diabetes.
1,132
Pioglitazone acts as an agonist to peroxisome proliferator activated receptor-gamma (PPAR-γ), and while it is often used to improve insulin sensitivity in diabetic patients, it has also demonstrated considerable benefit by suppressing symptoms associated with autistic behavior. 
Nano-Pharmaceuticals: Expanding the Therapeutic Toolbox
Given the limitations of currently available small molecule drugs, it seems that novel agents with unique mechanisms of action are necessary. Nanoparticles may provide a springboard for new pharmacological agents, particularly because they would facilitate efforts to address the dysregulated immune activity and oxidative stress that have been implicated in autism.
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In this regard, gold nanoparticles (AuNPs) are an interesting pharmaceutical candidate. Ghanizadeh et al. suggest that the administration of AuNPs with lipoic acid may alleviate symptoms of autism through numerous anti-inflammatory and anti-oxidant mechanisms, such as increasing glutathione peroxidase (GPx) activity and increasing the scavenging of free radicals. 135 This suggestion was corroborated by another study which found that AuNPs increased expression of anti-oxidant enzymes GPx, superoxide dismutase and catalase, with an associated increase in the plasma oxygen radical absorbance capacity of autistic mice. ; given that autism is characterized by a similar neuroinflammatory process, they propose that NAC-conjugated dendrimers have the potential to be developed as a possible treatment for autism. Interestingly, it has been noted that there is normally no observable transplacental movement of G4-OH PAMAM dendrimers in humans. 137 This means that prenatal therapies utilizing these dendrimers can be confined specifically to either the maternal or fetal compartment, allowing for separate regulation of maternal and fetal factors involved in autism.
It is worth emphasizing that although nanoparticles may be exquisitely suited to treat ASDs due to their unique structural and biochemical features, they may also offer an Interestingly, the benefits mediated by wild type microglia were diminished with pharmacological inhibition of phagocytic activity. This study thus supports the notion that dysregulated immunity is an important aspect of the development and/or progression of ASDs, and that that bone marrow stem cell transplantation might alleviate this pathological factor by augmenting phagocytic activity in the brain. Copyright © 2013 Frontiers Media S.A. Figure 9 illustrates the general mechanism of action of some novel proposed therapies for ASDs, although these therapies are still in their infancy.
